1. Home
  2. Analysis
  3. Gliclazide
  4. Imfinzi

Gliclazide and Imfinzi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gliclazide (gliclazide) and Imfinzi (durvalumab). Common drug interactions include interstitial lung disease among females and pneumothorax among males.

The phase IV clinical study analyzes what interactions people have when they take Gliclazide and Imfinzi. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in diabetes. eHealthMe is studying from 28,131 Gliclazide users. Check the latest studies of Gliclazide.

What is Imfinzi?

Imfinzi has active ingredients of durvalumab. eHealthMe is studying from 8,353 Imfinzi users. Check the latest studies of Imfinzi.

On Jul, 19, 2026

11 people who take Gliclazide and Imfinzi together, and have interactions are studied.

Gliclazide and Imfinzi drug interactions.

What are the common drug interactions of Gliclazide and Imfinzi, by gender? *:

female:

  1. Interstitial lung disease
  2. Death

male:

  1. Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung)
  2. Radiation pneumonitis (inflammation of lung due to radiation)
  3. Interstitial lung disease
  4. Lung disorder (lung disease)

What are the common drug interactions of Gliclazide and Imfinzi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Interstitial lung disease
  2. Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung)
  3. Radiation pneumonitis (inflammation of lung due to radiation)
  4. Lung disorder (lung disease)
  5. Phlebitis (inflammation of the walls of a vein)

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 36.36%
  2. Type 2 Diabetes: 1 person, 9.09%
  3. Small Cell Lung Cancer Extensive Stage (small cell lung cancer that has spread (metastasized) to other regions of the body such as another lobe of the lung or the brain): 1 person, 9.09%
  4. Lung Cancer - Small Cell (lung cancer): 1 person, 9.09%
  5. Lung Cancer - Non-Small Cell (lung cancer): 1 person, 9.09%
  6. Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 9.09%
  7. Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 9.09%
  8. High Blood Pressure: 1 person, 9.09%
  9. Dyslipidaemia (abnormal amount of lipids): 1 person, 9.09%
  10. Bronchial Carcinoma (lung cancer): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Gliclazide and Imfinzi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Gliclazide and Imfinzi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Gliclazide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Imfinzi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gliclazide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Imfinzi and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gliclazide and durvalumab (the active ingredients of Gliclazide and Imfinzi, respectively), and Gliclazide and Imfinzi (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.